Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 breast milk study of risankizumab in lactating women with inflammatory bowel disease
MOH_2024-04-18_013379Phase 4Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risankizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by AbbVie Inc. Started Mar 2024; status: recruiting.
02
Drugs
risankizumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on MOH_2024-04-18_013379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-18_013379.